Pharma Mar Valuation
| 0RC6 Stock | 97.80 1.70 1.77% |
At this time, the company appears to be overvalued. Pharma Mar SAU holds a recent Real Value of USD91.76 per share. The prevailing price of the company is USD97.8. Our model determines the value of Pharma Mar SAU from analyzing the company fundamentals such as Shares Outstanding of 221.28 M, operating margin of 0.12 %, and Return On Equity of 0.0032 as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 1.6 B | Price Sales 98.1217 | Trailing PE 0.1469 |
Overvalued
Today
Please note that Pharma Mar's price fluctuation is very steady at this time. Calculation of the real value of Pharma Mar SAU is based on 3 months time horizon. Increasing Pharma Mar's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharma stock is determined by what a typical buyer is willing to pay for full or partial control of Pharma Mar SAU. Since Pharma Mar is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharma Stock. However, Pharma Mar's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 97.8 | Real 91.76 | Hype 98.91 | Naive 96.67 |
The intrinsic value of Pharma Mar's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pharma Mar's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pharma Mar SAU helps investors to forecast how Pharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharma Mar more accurately as focusing exclusively on Pharma Mar's fundamentals will not take into account other important factors: Pharma Mar Cash |
|
Pharma Mar Total Value Analysis
Pharma Mar SAU is presently projected to have takeover price of 1.62 B with market capitalization of 16.39 B, debt of 43.67 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pharma Mar fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.62 B | 16.39 B | 43.67 M |
Pharma Mar Investor Information
About 27.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 5.03. Pharma Mar SAU had not issued any dividends in recent years. The entity had 0.083333:1 split on the 22nd of July 2020. Based on the analysis of Pharma Mar's profitability, liquidity, and operating efficiency, Pharma Mar SAU is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Pharma Mar Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Pharma implies not a very effective usage of assets in February.Pharma Mar Ownership Allocation
Pharma Mar owns a total of 221.28 Million outstanding shares. Pharma Mar has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pharma Mar Profitability Analysis
The company reported the revenue of 158.15 M. Net Income was 1.14 M with profit before overhead, payroll, taxes, and interest of 157.68 M.About Pharma Mar Valuation
The stock valuation mechanism determines Pharma Mar's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pharma Mar SAU based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pharma Mar. We calculate exposure to Pharma Mar's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pharma Mar's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 170.8 M | 114 M |
Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.